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The role of solvent swelling in the self-assembly
of squalene based nanomedicines†
Debasish Saha,a Fabienne Testard,a Isabelle Grillo,b Fatima Zouhiri,c
Didier Desmaele,c Aurel Radulescu,d Sylvain Desert,e Annie Brulet,e
Patrick Couvreurc and Olivier Spalla*a
Squalene based nanoparticles obtained via nanoprecipitation are promising candidates as eﬃcient anti-
cancer drugs. In order to highlight their preparation process and to facilitate further clinical translation,
the present study enlightens the paramount role of the solvent in the formation of these nanomedicines.
Three diﬀerent squalene-based nanoparticles, i.e. squalenic acid, deoxycytidine squalene and gemcitabine
squalene, have been investigated before and after organic solvent evaporation. Size and structural analysis
by Small Angle Neutron Scattering revealed that droplets’ size was uniquely controlled by the solvent
composition (ethanol–water), which evolved during their gradual formation. The particles were preferably
swollen by water and the swelling increased when less ethanol was present. Either coalescence or
fragmentation was observed depending on the increase or decrease of the ethanol content, supporting
an equilibrium control of the size. Moreover, a high water swelling was observed for the three local
organization of the nanodroplets (hexagonal for gemcitabine squalene, cubic for deoxycytidine and not
structured for squalenic acid) and could be the source of the previously reported efficiency of related
anti-cancer squalene based nanomedicines.
1. Introduction
Increasing the amount of therapeutic agent reaching the desired
biological target is one of the key points motivating all the
present endeavors in nanomedicine. In this context, various
nucleoside analogues with anticancer or antiviral pharmaco-
logical activity have been conjugated to squalene, a natural
and biocompatible lipid (i.e., squalenoylation technology). The
resultant conjugates were found to display an amphiphilic
character and a precipitation method by solvent displacement
provided the spontaneous formation of nanoparticles in water.1,2
Among others, this concept has been applied to gemcitabine, an
anticancer agent, prescribed in first intention for the pancreatic
cancer.3 It was observed that the so-called squalene-gemcitabine
nanoparticles (SQ-gem NPs) were able to inhibit gemcitabine
metabolization in human plasma, to increase the absorption in
lymphoid organs4 after both intravenous and oral administra-
tion and to prolong the concentrations of gemcitabine in the
plasma after intravenous administration.5 In vitro and in vivo
experiments have demonstrated an increased anticancer activity
in experimental models of leukemia6,7 and pancreatic cancers8
and these nanoparticles were even found to overcome some
mechanism of resistance,9 including the down regulation of
nucleoside transporters or the insuﬃcient phosphorylation
by deoxycytidine kinase. One of the most intriguing aspects of
this eﬃcient nanomedicine results from the spontaneous self-
assembly of the gemcitabine-squalene prodrug into nanoparticles.
The unique property of squalene to adopt a dynamically folded
molecular conformation in aqueous media is likely a key, but
the mechanism allowing the formation of these nanoparticles,
as well as, the events occurring during the nanoprecipitation of
the SQ-gem bioconjugate remained unclear and deserved to be
investigated. This is a very important question, because of
the translation from the bench to the bed side and the design
of a clinical sample needs a better understanding of nano-
particle elaboration. Thus, by using Small Angle Neutron
Scattering (SANS), we investigated the formation process of
the squalenoyl derivative nanoparticles, their size distribution,
the solvent nanoparticle inner content and the nanostructure of
gemcitabine-squalene (SQ-gem) and two other derivatives, the
deoxycytidine-squalene (SQ-dC) nanoparticles and squalenic
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acid (SQ-CO2H) used as precursors in the synthetic procedure
of squalenoyl compounds.
We observed drastic changes in the size, the swelling by solvent
and the number density of particles along the gradual formation
of SQ-dC and SQ-gem nanoparticles. These facts support the
conclusion of a thermodynamically driven formation providing
nanoparticles in equilibrium with their solvent environment.
These results obtained in the field of squalenoylation technology
impact the global understanding of the formation of prodrug
nanoparticles10 and should help to reach a better control over
size and stability of such very promising systems for enhanced
drug activity and delivery.
2. Experimental
2.1 Materials and characterization of squalene molecules
Squalenic acid, deoxycytidine squalene and gemcitabine squalene
(Fig. 1) were synthesized following the protocol described by
Desmaele et al.1,11 The Table 1 summarizes the physical charac-
teristics used for scattering calculation of the diﬀerent squalenoyl
derivatives. Absolute ethanol (499.8%) was purchased from
Sigma-Aldrich, Germany and D2O (99.85% D) was purchased
from Euriso-top.
2.2 Preparation of nanoparticles (NPs)
The nanoparticles were prepared by nanoprecipitation, which is a
simple one-stepmethod consisting of the addition of the squalene
bioconjugate dissolved in an organic solvent to an aqueous
phase.12–14 As presented in Fig. 2, this mixing step yields the
intermediate states of nanoparticle formation. The organic
solvent was then evaporated producing the final state of the
nanoparticle preparation.
In a first step, a certain amount of squalenoyl conjugate
(either SQ-gem, or SQ-dC, or SQ-CO2H) was properly dissolved
in a suitable organic solvent, here ethanol. This solution was
then added drop by drop by means of a syringe pump (PHD
2000, Harvard Instruments) into an aqueous phase (D2O) under
moderate magnetic stirring (500 rpm). The injection rate
was 3.0 mL min1 for all the samples. D2O was used as the
solvent instead of H2O to increase the scattering length density
neutron contrast between the nanoparticles and the solvent.
The progressive mixing of squalene derivated solution with D2O
formed the intermediate states of the ‘‘nanomedicine’’ prepara-
tion. In the final step, the ethanol content was reduced to
minimum by concentration using a Rotavapor around 40.0 1C
and controlled vacuum (100 mbar).15 This step was repeated
several times until the weight loss of the sample was equivalent
to the initial amount of added ethanol used to prepare the
sample. Finally, it was observed that a fraction of water or D2O
co-evaporated with ethanol. This makes harder to interpret by
weight measurements the exact amount of ethanol eliminated
during solvent evaporation. Fortunately, the exact content of
ethanol could be checked by the level of incoherent scattering
(see SV, ESI†). The evaporation of ethanol yielded the final state
of nanoparticles which could be used for eventual pharmaco-
logical assays.16 SQ-dC nanoparticles were more stable than
SQ-CO2H while SQ-gem nanoparticles displayed conditional
stability. It was observed that the gemcitabine squalene inter-
mediate states were less stable (only for a few hours), while the
final state was stable up to a month, at controlled temperature
(around 25.0 1C). It was also found that SQ-dC nanoparticles were
stable from few weeks to months (by Dynamic Light Scattering
(DLS), the identical size was also found after few months for the
intermediate state of deoxycytidine squalene nanoparticles). The
final state of the nanoparticles was prepared in the laboratory
from a few days to one week before the neutron scattering
experiment, while nanoparticles at intermediate states were
prepared in the Chemistry laboratory of the neutron facilities
(Institute Laue Langevin (ILL-Grenoble)); JCNS (Juelich Centre for
Neutron Science), FRMII, Garching and Laboratory Le´on Brillouin
Fig. 1 Molecular structure of diﬀerent squalenoyl molecules. (A) Deoxy-
cytidine squalene (SQ-dC) (B) gemcitabine squalene (SQ-gem) (C) squalenic
acid (SQ-CO2H).
Table 1 Characterization of diﬀerent squalenoyl molecules in terms of

















C36H55N3O5 609.8 7.70  109
Gemcitabine
squalene
C36H53N3O5F2 645.8 0.858 8.77  109
Squalenic acid C27H44O2 400.6 3.42  109
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(LLB-Saclay), immediately before neutron scattering measure-
ments. The final concentration of the squalenoyl derivatives is
obtained by UV-Vis measurements as explained in SVII (ESI†).
The whole list of prepared samples is given in the SI (ESI†).
2.3 Characterization of the nanoparticles
2.3.1 Small Angle Neutron Scattering (SANS). The range of
concentration of squalene entities that could be reached by this
method was rather low and Small Angle Neutron Scattering
(SANS) was preferred over the more classical (and accessible)
Small Angle X-ray Scattering (SAXS) to analyze the structure of
these nanomaterials.17,18 Indeed, the low contrast between solvent
and organic moieties was not favorable for SAXSmeasurements of
intermediate states. In contrast, using neutrons allows a strong
increase of the contrast provided that deuterated water was used
as a solvent to take benefit from the large diﬀerence between
hydrogen and deuterium atoms. Experimental configurations and
treatment methods are presented in SII, SIV and SV (ESI†).
2.3.2 Dynamic Light Scattering. DLS was carried out using
a Zetasizer (MALVERN Instruments) at 20 1C. All the samples
used for DLS measurements were diluted in D2O by a factor of
50 to avoid multiple scattering. The DLS distribution of the size
in number was reconstructed from the volume distribution
yielded by the Malvern instrument analysis (used to recover the
correct decrease of the autocorrelation function).
3. Results and discussion
3.1 Deoxycytidine squalene nanoparticles (SQ-dC NPs)
SANS patterns of a series of deoxycytidine squalene intermediate
states with an increasing number of added drops corresponding
to increasing concentrations of deoxycytidine squalene in the
overall solution are presented in Fig. 3A. Even for the lowest
concentration, the SANS signal from the nanoparticles was much
higher than the background allowing a clear description of the
sequence of events. Focusing on the high-q regime first, two
Bragg peaks appeared at 0.060 Å1 and 0.085 Å1 for the
concentration above 0.96 mg mL1. This was the signature of
an internal structure of the nanoparticles from the initial
steps of their formation. Ethanol was then evaporated which
yields the final state. The final state at diﬀerent concentrations
in the overall solution is presented in Fig. 3B. At large angles,
only a unique intense Bragg peak was clearly visible (at 0.09 Å1)
in contrast to the intermediate stage case. This modification
induced by the evaporation step supports a control of the
nanoparticles’ internal structure by the activity of the solvent which
modifies the phase diagram of the deoxycytidine squalene–water–
ethanol system. On the other hand, the Bragg peak position in
the final state was weakly sensitive to the deoxycytidine squalene
concentration and in agreement with results previously obtained
by SAXS on concentrated solution of deoxycytidine nanoparticles
in water which reported the cubic structure.19 We could also
confirm the cubic structure using Wide Angle X-ray Scattering
(WAXS) directly on the present diluted solutions (see the inset
in Fig. 3B).
Turning to the middle q-range, the scattering curves oﬀered
significant information about the interfacial structure of these
nanoparticles with the surrounding solvent. The signal decreased
with a power law of q4 (called the Porod regime20) in the q
range B0.004 Å1 to 0.01 Å1 in the intermediate state and in
the q range B0.004 Å1 to 0.02 Å1 in the final state revealing
abrupt interfaces between the nanoparticles and the solvent at
the scale of a few nanometres.
At low angles, the scattering intensity saturated revealing a
limited size for the structure under development in the inter-
mediate states. However, due to a limited q range (qexp 4
1.4 103 Å1), the saturation regime was not attained and a
Guinier analysis21,22 of the signal at low q could only indicate
that the nanoparticles were bigger than 150 nm since the first
drops. The higher upturn at low q with concentration also
revealed that particles were getting bigger.
At the final state the low-q upturn of the scattering intensity
was almost independent of the squalene derivative concentration.
Fig. 3 (A) SANS patterns (ILL, D22) of the intermediate state of deoxycytidine
squalene nanoparticles obtained during drop by drop addition of ethanol–H
solution (5.48 mgmL1) into D2O. In the inset a zoom at wide angle shows the
appearance and variation of a Bragg peak. (B) SANS patterns (ILL, D22) of the
final state at different concentrations after evaporation. In the inset a zoom at
wide angle (SANS and WAXS for the 3.73 mg mL1 sample) evidences the
internal structure. The concentrations (in mg mL1) of squalenoyl compounds
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For the highest concentration of deoxycytidine squalene
(C = 3.73 mg mL1), a trend towards saturation was observed
revealing nanoparticles of smaller size than for the inter-
mediate states and disclosed a second eﬀect of the evaporation
of ethanol that was to reduce the size of the initially precipi-
tated nanoparticles.
3.2 Gemcitabine-squalene nanoparticles (SQ-gem NPs)
Since it has been observed that nucleosides containing diﬀerent
head groups lead to diﬀerent local organizations and in order to
investigate the influence of the nucleoside moiety on the nano-
particle formation,19 we compared SQ-gem NPs to SQ-dC NPs at
intermediate and final states. Unfortunately, intermediate states
of SQ-gem NPs prepared in ethanol–H/D2O tend to coalescence
on the time scale of hours making SANS not fully reliable for
long term analysis. In contrast, at the final state they displayed
longer term stability, and their SANS diagrams (which were
obtained in an extended q range) are reported in Fig. 4.
Focusing on the high-q regime first, a Bragg peak could be traced
around 0.12 Å1 from the lowest concentration of gemcitabine
squalene (1.83 mg mL1). This unique Bragg peak matched quite
well with the value of the second order Bragg reflection of the
hexagonal phase reported in the literature for gemcitabine squalene
nanoparticles.23 Additionally, the position of the Bragg peaks in the
final state has been confirmed by using SAXS directly on the present
diluted solutions (see the inset in Fig. 4). The absence of the first
order Bragg peak was due to the presence of aminimum in the form
factor of the inner pore structure.
Interestingly, in the final state, the Guinier regime below
2  103 Å1 is still measurable for the highest concentration of
SQ-gem (C = 3.01 mg mL1). Particles were bigger than for the
deoxycytidine case. In contrast to the SQ-dC NPs, the low-q upturn of
the scattering intensity clearly depended on the concentration.
3.3 Squalenic acid nanoparticles (SQ-CO2H NPs)
To further extend the view of the hydrophilic head eﬀect, we
also studied the particle formation of one of the parent
molecules i.e. squalenic acid (SQ-CO2H), which possesses a
diﬀerent head group from deoxycytidine squalene and gemcitabine
squalene. The results are presented in the SIII, ESI.†
3.4 Determination of size distribution
A full fitting of SANS patterns was used to extract the number
of particles per liter N, size distribution f (r) and internal
composition Dr of SQ-dC, SQ-gem and SQ-CO2H nanoparticles.
In the absence of any interaction between these nano-objects
(valid approximation under the present diluted conditions), the
scattering from a population of spherical objects was given by:
I(q) = NDr2
Ð
f (r)V2(r)F2(q,r) dr (1)
where V(r) and F2(r) were the volume and the form factor of a
spherical particle of radius r. The matching of experimental
data with eqn (1) yields f (r) through q-dependence and N(Dr)2
through the absolute intensity unit scaling. As shown in Fig. 5,
the best result was obtained for a population of spheres with a
log-normal distribution for both final and intermediate states.
The fit with the q-dependence provided the distribution which
could be compared to the one obtained by the Dynamic Light
Scattering (DLS) analysis (the inset in Fig. 5A).
3.5 Determination of swelling
Beyond the size distribution given by f (r), the full fitting allowed
the extraction of the internal composition of the nanoparticles.
Indeed, assuming a composition of the nanoparticles implied a
value for Dr (see SIV, ESI†), thus a value for N through N(Dr)2.




f (r)V(r) dr (2)
and compared to the experimentally known volume fraction FSq
of squalene derivatives added into the solution. Surprisingly,
assuming that the nanoparticles were only made of squalene
conjugates yielded a calculated volume fraction far too high in
comparison to the added content. Hence nanoparticles had to
be swollen.
Therefore, a swelling factor Ftot = Ftot,SANS of the nano-
particles was introduced to overcome this discrepancy. The
nanoparticles could be swollen either by solvent which was a
mixture of water and ethanol or by water alone or by ethanol
alone.24 Assuming a type of swelling and a swelling factor
a yielded again a specific (see SIV, ESI†) Dr, then N and finally
Ftot,SANS by eqn (2). This method was eﬀective and gave drastic
results: the swelling by pure ethanol (a would be below one)
and the swelling by the solvent (a would be beyond 20) yielded
unrealistic values. Only the hypothesis of a swelling by pure
water produced coherent results with Ftot = Ftot,SANS and in the
range 1–10. A first strong conclusion is thus that these nano-
particles were swollen by water.
In the case of intermediate states, the water–ethanol com-
position of the solvent was calculated straightforwardly from
the composition of the sample. For the final states, we used the
values of the incoherent background measured at large angles
as explained in the SV (ESI†). This revealed that even the final
Fig. 4 SANS patterns (LLB, PAXY and TPA) of the final state of gemcitabine
squalene nanoparticles at diﬀerent concentrations. In the inset, a zoom at
wide angle neutron (full symbol) and X-ray scattering (empty symbol)
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state did contain a large amount of ethanol and that a partial
co-evaporation of water with ethanol occurred. Accordingly, we
did not rely on the weight of the samples after evaporation to
ascertain that ethanol has been withdrawn.25 The values of the
swelling factor a for the three squalene derivatives versus the
composition of the solvent are reported in Fig. 6. Four major
conclusions can be drawn. For the intermediate and final states
of deoxycytidine squalene nanoparticles, the swelling was
decreasing with the addition of ethanol solution. Additionally,
the swelling was between 2 and 11. It is also remarkable that in
the intermediate state, SQ-CO2H nanoparticles followed the
similar trend of swelling to SQ-dC. Finally, it was found that the
swelling of SQ-gem NPs was lower than that of SQ-dC NPs.
These findings evoke a conclusion that the swelling not only
depended on the composition of the solvent but also on the
chemical nature of the hydrophilic head of the conjugate. The
presence of two fluorine atoms on the polar head of SQ-gem
reduced the hydrophilic character of the cytidine nucleus and
thus strongly influenced the packing parameter of SQ-gem with
a direct consequence on the swelling.23
3.6 Discussion on the pathway of formation
The analysis of SANS diagrams using the water swelling model
also yielded the evolution of number density and size distribution
during nanoparticle formation using eqn (1). The results are
reported in Fig. 7 for the three types of nanoparticles.
Along with the addition of deoxycytidine squalene ethanol
drops in water (Fig. 7A), the smallest detected diameter was
42 nm. It became bigger with the increasing number of drops.
Regarding the number density of nanoparticles, a bias was that
along the addition of drops, both the squalene derivative
concentration and the fraction of ethanol increased. To take
into account this bias and measure solely the impact imposed
by the systematic gradual change of solvent, the concentration
of the nano-objects was normalized by the concentration of
squalenoyl derivatives (in mg mL1). These number densities
normalized to a common concentration of 1 mg mL1 (named
‘‘Norm conc.’’) are reported in Fig. 7 and unravel clearly that
coalescence occurred for the addition of every drop since the
first one. However, all the samples in the series of the inter-
mediate states for SQ-dC were stable for days. This stability
with time for a given composition of solvent implies that the
coalescence occurred only during the addition of drops and the
induced change of solvent. Noteworthy, the change in size was
Fig. 5 (A) Fitting results of SANS intensity (ILL, D22) by eqn (1) with
added incoherent background of SQ-dC nanoparticles at the final state
(C = 3.73 mg mL1). In the inset, the comparison between DLS and SANS
distribution of the same sample is shown. (B) Fitting results of SANS
intensity (FRM2, KWS2) by eqn (1) with the added incoherent background
of SQ-gem nanoparticles at the intermediate state (C = 0.41 mg mL1).
Fig. 6 Swelling factor a versus the ethanol fraction of the solvent for the
intermediate states of SQ-dC and SQ-CO2H nanoparticles and final states
of SQ-dC and SQ-gem nanoparticles.
Fig. 7 Diameter in nm (circles) and normalized number density in cm3 mg1
(diamonds) versus ethanol fraction in solvent for intermediate states
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associated with a change in solvent composition, but not with a
change in concentration.26
Hence, the size was controlled by the solvent composition,
which evolved with the increase of ethanol in the D2O solution.
Indeed, ethanol was a lesser good solvent than water for the
hydrophilic moieties of the squalenoyl conjugates. On the
other hand, mobility measurements have shown that the
colloidal stability of the nanoparticles was ensured by a
negative zeta potential.27 This negative charge can only come
from adsorbed residual charges at the surface of squalenoyl
conjugate hydrophilic heads (helped in this by the strong inner
swelling of the nanoparticles by water). So, the stabilization
being electrostatic, when the solvent polarity was decreasing,
the stability was also decreasing as shown by the colloidal
stability theory.28
An intriguing question is therefore, why did the coalescence
stop? Again, colloidal stability tells that when the charge was
getting bigger on the objects, the stability was getting higher.
Thus after a certain stage of coalescence, the global charge of
the nano-objects increased and the stability was recovered.
It can therefore be concluded that the samples were at the
equilibrium of swelling and internal organization, controlled by a
thermodynamically intensive parameter that was the solvent com-
position. This was also valid for the final state samples of SQ-dC
since the diameter and number values in Fig. 7 are overlapping
the ones obtained for the intermediate states.
Consequently, an emerging question is the sequence of events
occurring during the evaporation of ethanol. Indeed, during the
addition of ethanol, a de-swelling of the sample and a gradual
coalescence toward an equilibrium size were observed. Reversibly,
when ethanol was evaporated from the sample, the number
density of the nano-objects increased; their size was reduced,
even if in the meantime they were more swollen by water. It was
therefore concluded that a fragmentation of the objects occurred
during the ethanol evaporation stage (Fig. 8).
Now, these conclusions were obtained for SQ-dC. But the same
was also observed with SQ-gem nanoparticles in deuterated ethanol,
used instead of hydrogenated ethanol which yielded more stable
samples allowing the SANS measurement to be performed for the
intermediate states (see SVI, ESI†). A similar influence of ethanol
fraction was observed for SQ-CO2H with a stronger dependence
of the swelling on the ethanol content and the coalescence eﬀect.
In this case, quite big assemblies (d = 118 nm) were formed,
even at the lowest experimental concentration (c = 0.63 mg mL1)
or ethanol fraction.
Finally, looking only to the final state (which is the only one
used in anti-cancer treatment), it appears that gemcitabine
squalene produced the best monodispersed sample. Indeed,
the variances of the log-normal distribution extracted from the
fits were much lower for SQ-gem nanoparticles (0.27–0.31) than
for SQ-dC nanoparticles (0.4–0.45). Those were also bigger in
size (as reported in Fig. 7B as compared to Fig. 7A) and very
sensitive to the residual amount of ethanol. However, they were
still in a size range below 200 nm fully usable for medical
applications. For SQ-CO2H nanoparticles, the size in the final
states could not be extracted from the SANS fits (no Guinier
regime), demonstrating that the scheme was different than in
the case of deoxycytidine and gemcitabine. The influence of
the ‘‘aging effect’’ was clearly observed for the final states of
SQ-CO2H nanoparticles, pushing the particles to be aggregated
and form larger nanoassemblies, which is out of the typical size
range of squalenoyl prodrugs (25–300 nm).
Importantly, the swelling factors for the final states of SQ-gem
nanoparticles were around 2. This is less than for SQ-dC nano-
particles, but still quite high which means that these eﬃcient
nanodrugs were made of 50% water. Coupling this high swelling
with the hexagonal phase also means that the gemcitabine
moieties, which were at the inner surface of the hexagonal
channels, would be available for release upon enzymatic cleavage
through these large water channels, thus inducing an eﬃcient
killing of cancer cells, as reported previously.29
4. Conclusions
The emerging paradigm arising from the present study is that
the size obtained for these nanomedicines results from thermo-
dynamic equilibrium, with a preferential swelling by water in a
mixed water–ethanol solvent and residual charge stabilization.
The important message is that the control of the solvent com-
position is thus of crucial importance for the size control and
further scaling-up for eventual clinical translation. Noteworthily,
in the most ethanol depleted solvent (final state), the nano-
particles presented a highly swollen inner structure and a size
distribution below 200 nm well adapted for clinical applications.
The direct access by large water channels to the inner content of
drugs contributes to their reported improved efficiency.29
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